In patients with HL, local inner ear delivery through a micropump or gel of these small molecules may be preferable to systemic administration of a drug increasing the SLC26A4 half-life at the plasma membrane to avoid regulatory changes of SLC26A4 in the kidney, in particular. The gene discussed is SLC26A4; the disease is Hodgkins lymphoma.